Skip to content

a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea

a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01447004
Enrollment
100
Registered
2011-10-05
Start date
2010-03-31
Completion date
Unknown
Last updated
2011-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Brief summary

Heavy metal has been reported that it can cause attention deficit and behavioral disturbance. The investigators hypothesis is that heavy metal is associated with children with attention deficit/hyperactivity disorder(ADHD).

Interventions

None listed

Sponsors

Hallym University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects must meet DSM-IV criteria for ADHD based-on the K-Schedule for affective disorder and schizophrenia(K-SADS-PL-K) interview * Subjects signed a written consent form voluntarily. * Patient 's assent to participate in the study and written informed consent form signed by one of the parents, parent surrogates, or legal guardian. * Subjects/parents, parent surrogates or legal guardian who can understand the participation of the study and voluntarily withdraw from the study at any time

Exclusion criteria

* Subjects who have any history of bipolar disorder, psychotic disorder, and substance use disorder, have been diagnosed with a pervasive developmental disorder, organic brain disease and seizure disorder. * Subjects who have significant suicidal ideation or homicidal ideation * Subjects with mental retardation * Subjects with Tourette's syndrome requiring drug therapy. * Subjects who currently have a significant medical conditions (e.g. diseases of cardiovascular, hepatic, renal, respiratory, glaucoma). * Subjects who have abnormalities in the ECG or show clinically significant abnormalities of laboratory results, including serum chemistries and hematology. * Subjects who have been administrated alpha-2 adrenergic receptor agonist,antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant within recent 2 months. * Subjects who dyed their hair within 8 weeks

Countries

South Korea

Contacts

Primary ContactHyun Ju Hong
hongdr@chol.com, hjhong@hallym.or.kr+82-31-380-3750

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026